Alnylam Pharmaceuticals CEO discussed the expansion of their heart drug vutrisiran, which is effective in treating ATTR cardiomyopathy. The company’s stock reached an all-time high, exceeding $38 billion in market value. Merck’s new data suggests competition for AstraZeneca and Sanofi’s RSV prophylactic Beyfortus. The potential approval of clesrovimab could offer advantages over Beyfortus in preventing RSV-related hospitalizations. Biotech investors are interested in autoimmune disease treatments, and Genentech advocates for a long-term bipartisan approach to lower drug costs. Evidence suggests a viral cause of dementia, and FDA delays a decision on Amgen’s colorectal cancer drug. Consumer groups urge FTC to block Catalent sale to Novo Holdings.
Source link
Alnylam, RSV, Genentech, Amgen, FDA latest
